DS
EPRS

David Shaw’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

David Shaw’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-30,032
Closed -$216K – 4566
2014
Q3 		$216K Buy
+30,032
New +$260K ﹤0.01% 3862

Other funds holding EPRS

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

David Shaw's EPRS Position: Q4 2014 in Review

David Shaw sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q4 2014, closing a stake of 30,032 shares — an estimated $216K sold.

David Shaw first reported a position in EPRS in Q3 2014 and held it in 1 quarter. The position peaked at $216K in Q3 2014. 24 funds tracked by Wall St. Rank hold EPRS as of Q4 2014.

  • David Shaw reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q4 2014 after selling out during the quarter.
  • David Shaw sold 30,032 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q4 2014, an estimated $216K.
  • David Shaw first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q3 2014 and held it in 1 quarter.
  • David Shaw's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $216K in Q3 2014.
  • 24 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q4 2014.

Based on D.E. Shaw & Co's 13F filing for Q4 2014, filed 17 Feb 2015.